Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases — Stella

Home/Non-Small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Non-Small Cell Lung Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Hunan Cancer Hospital, Changsha, Hunan

Key details

Phase

Safety & dosing

Sponsor

Hunan Province Tumor Hospital

Collaborators

Hunan Cancer Hospital

Enrollment target

~220 participants

Started

May 2024

Primary completion

December 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years and older

Last updated June 2024